270 likes | 378 Views
System-wide impact of chronic care payment schemes in Europe: evidence from an empirical analysis. Apostolos Tsiachristas, Carolien Dikkers, Melinde Boland, Maureen P.M.H. Rutten- van Mölken ICIC, Berlin, 11 April 2013 . Content. Background Aim & Methods Results
E N D
System-wide impact of chronic care payment schemes in Europe: evidence from an empirical analysis Apostolos Tsiachristas, Carolien Dikkers, Melinde Boland, Maureen P.M.H. Rutten- van Mölken ICIC, Berlin, 11 April 2013
Content • Background • Aim & Methods • Results • Discussion & Conclusions
The economic burden of chronic diseases • Chronic diseases are related to (WHO,2007): • 60% of all deaths • 75% of total health care expenditure • Other costs: disability, premature mortality, work absence, reduced productivity, early retirement, informal care • This threat increases due to: • increasing prevalence • multi-morbidity • Chronic diseases account largely for the increasing health care expenditure!
Integrated chronic care (ICC) • Chronic diseases: complex, indefinite duration,multiple causes, interaction with many different care providers • Elements of ICC: • collaboration & coordination • care plan • multi-disciplinary professional teams • active role of patient • prevention & risk management • Aim: to increase patients’ QoL and cost savings (in the long run) • Prerequisite: payment scheme that provides adequate financial flows and incentives
Lack of evidence • Overview of payment schemes for ICC in EU • How were implemented • What were the facilitators and barriers • What was the impact on health care expenditure • national level • different categories of expenditure
Content • Background • Aim & Methods • Results • Discussion & Conclusions
Aim Investigate the impact of different payment schemes of chronic care on health care expenditure and Identify facilitators for and barriers to their success
Methods & Data • Literature review to identify payments on national level & countries with such schemes • Interview template (A: semi-open questions, B: rating) • 15 interviews with experts in chronic care (payments) in 6 countries • Empirical policy impact analysis using difference-in-differences (DID) models • Panel data (1996-2010) for 26 European countries from WHO & OECD • Independent variables of interest (payment schemes) • Outcome variables (expenditure categories) • Other covariates (GDP per capita US$PPP, total employment per 1000 inhabitants)
Payment schemes for ICC • Pay-for-coordination (PFC): payment forcoordination of care provided by different care providers (AUS, DEN, FRA) • Pay-for-performance (PFP): payment or financial incentive associated to improvements in the process and outcomes of chronic care (ENG, FRA) • All-inclusive payments including: • Bundled payment for a group of services for a specific diseaseinvolving multiple providers (NL) • Global payment, risk-adjusted payment for the full range of services related to specified group of people (GER)
Why DID • Panel data (FE): • unobserved (time-invariant) effect • First differences: Parallel & Linear !?
DID models • Parallel trends (PT): • Random trends (RT): • Differential trends (DT): • Time lagged models( , , )
Model specifications • Estimation of variance (robust or cluster-robust): • Heteroscedasticity (Breush-Pagan/Cook-Weisberg test) • Autocorrelation (Langram-Multiplier test) • Multicollinearity (VIF) • Select model: • Bayesian information criterion (BIC) • Joint significance • Generalised Hausman test
Content • Background • Aim & Methods • Results • Discussion & Conclusions
Overview of predominant chronic care payment schemes in outpatient care per country by year
Perceived effects of integrated chronic care payment schemes ++ =strongly agree; +=agree; ?=neutralor unknown; - = disagree; -- = strongly disagree
Results from the main DID models • * p-value<0.05; **p-value<0.01; ***p-value<0.001; other covariates included in the model were: GDP, total employment in health care; the impact is calculated dividing the respective coefficient by the mean (denoted as μ)of the respective outcome variable
Results from the time lagged DID models • p-value<0.05; **p-value<0.01; ***p-value<0.001; other covariates included in the model were: GDP, total employment in health care; • the impact is calculated dividing the respective coefficient by the mean of the respective outcome variable; ALL: all-inclusive
Linear combined effect of each payment after 4 years of implementation
Content • Background • Aim & Methods • Results • Discussion & Conclusions
Discussion • Complementary value of qualitative and quantitative analysis • Immediate impact (none on total HC expenditure) • PFC: (+) medication & administrative • PFP: (+) medication, (-) hospital & administrative • All-in: (-) medication • Turbulent & long implementation process (incl. reactions) • Within 4 years after implementation • PFC: (+) medication • PFP: (-) hospital & administrative • All-inclusive: (+) total & hospital
Discussion • PFC: • Increased initially administration expenditure, due to overhead costs and GP opposition (?) • Increased medication costs, due to better adherence(?) • Initiated collaborations & was combined with PFP/ALL • PFP: • Most able to tackle HC expenditure growth • Faced with fewer barriers • Concerns about “gaming” and measuring • Failed to promote collaborations • All-inclusive: • Strongest impact on total HC expenditure • Increased hospital expenditure after 2 years, due to “gaming” (?) • Volatile implementation
Conclusions • Payment schemes are powerful tool to stimulate integrated care and influence health care expenditure • Selection based on international experiences & own potentials • Payment reforms designers should: • Fine-tune financial incentives & stimulate cooperation • Impose controls for rogue behavior • Increased expenditure are investments in future cost-savings (?) • Blended payment scheme: global payment including coordination costs that depends (partially) on performance indicators (examples from the US)
Limitations • Limited number of interviewees • No control for the non-payment related policies • No interviews in Portugal, Hungary, Estonia • Distinction between bundled & global payments • No outpatient care expenditure • Other outcomes (e.g. health outcomes)
Thank you for the attention! Questions? tsiachristas@bmg.eur.nl